Body mass index and prognosis in HER2-positive metastatic breast cancer patients

被引：0

作者：

Poletto, E. ^{[1
]}

Minisini, A. M. ^{[1
]}

Ferreira, A. ^{[2
]}

Matteo, L. ^{[3
]}

Poggio, F. ^{[3
]}

Sottotetti, F. ^{[4
]}

Montemurro, F. ^{[5
]}

Pozzi, E. ^{[4
]}

Rossi, V. ^{[5
]}

Risi, E. ^{[6
]}

Dellepiane, C. ^{[7
]}

Sini, V. ^{[8
]}

Ziliani, S. ^{[9
]}

Minuti, G. ^{[10
]}

Mura, S. ^{[11
]}

Grasso, D. ^{[12
]}

Bertolini, I. ^{[13
]}

Del Mastro, L. ^{[3
]}

Puglisi, F. ^{[14
]}

机构：

[1] Azienda Osped Santa Maria Della Misericordia, Dept Oncol, Udine, Italy

[2] Hosp Santa Maria, Inst Med Mol, Dept Med Oncol, Lisbon, Portugal

[3] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[4] Fdn Maugeri IRCCS, Unita Dipartimentale Oncol Med, Pavia, Italy

[5] Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo, Italy

[6] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[7] IRCCS AOU San Martino IST, Clin Oncol Med, Genoa, Italy

[8] Univ Roma La Sapienza, St Andrea Hosp, Oncol Unit, I-00185 Rome, Italy

[9] Osped San Paolo, Oncol Med, Savona, Italy

[10] Ist Tumori Toscano, Dept Med Oncol, Livorno, Italy

[11] Osped Santissima Annunziata, Dept Med Oncol, Sassari, Italy

[12] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[13] Azienda Osped Univ Pisana, Dept Oncol, Polo Oncol, Pisa, Italy

[14] Univ Hosp, Dept Oncol, Udine, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30811-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1861

引用

页码：S285 / S286

页数：2

共 50 条

[41] QOL-enhancing surgery for patients with HER2-positive metastatic breast cancer
Kai, Masaya
Kubo, Makoto
Kawaji, Hitomi
Kurata, Kanako
Mori, Hitomi
Yamada, Mai
Nakamura, Masafumi
BMJ SUPPORTIVE & PALLIATIVE CARE, 2019, 9 (02) : 151 - 154
[42] PERTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER
Smith, M. B.
Reardon, J.
Olson, E. M.
DRUGS OF TODAY, 2012, 48 (11) : 713 - 722
[43] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
F Carabantes-Ocón
E Saez-Lara
L Burgos-Garcia
E Villar-Chamorro
A Casaus-Hazañas
S Luna
C Martínez
Breast Cancer Research, 9
[44] Molecular heterogeneity of HER2-positive breast cancer: Prognosis and prediction
Kreklau A.
Aktas B.
Der Gynäkologe, 2018, 51 (10): : 870 - 877
[45] HER2-positive breast cancer
Loibl, Sibylle
Gianni, Luca
LANCET, 2017, 389 (10087): : 2415 - 2429
[46] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey, Naomi
Sandoval, Ana
Mahtani, Reshma
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1120 - 1137
[47] NEW DRUG APPROVED FOR HER2-POSITIVE METASTATIC BREAST CANCER
Aschenbrenner, Diane S.
AMERICAN JOURNAL OF NURSING, 2020, 120 (04) : 23 - 23
[48] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
Milani, Andrea
Montemurro, Filippo
Gioeni, Luisa
Aglietta, Massimo
Valabrega, Giorgio
BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
[49] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
Perez, Jose
Garrigos, Laia
Gion, Maria
Janne, Pasi A.
Shitara, Kohei
Siena, Salvatore
Cortes, Javier
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
[50] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Murthy, R. K.
Loi, S.
Okines, A.
Paplomata, E.
Hamilton, E.
Hurvitz, S. A.
Lin, N. U.
Borges, V.
Abramson, V.
Anders, C.
Bedard, P. L.
Oliveira, M.
Jakobsen, E.
Bachelot, T.
Shachar, S. S.
Mueller, V.
Braga, S.
Duhoux, F. P.
Greil, R.
Cameron, D.
Carey, L. A.
Curigliano, G.
Gelmon, K.
Hortobagyi, G.
Krop, I.
Loibl, S.
Pegram, M.
Slamon, D.
Palanca-Wessels, M. C.
Walker, L.
Feng, W.
Winer, E. P.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609

← 1 2 3 4 5 →